Insilico Medicine is a privately held company tracked for investment-relevant business and technology developments.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
Insilico's Chemistry42 platform invented Rentosertib (Phase 3 for IPF) which shifted six protein aging clocks toward 3-6 years younger biology; peak effect at week 4 shows 3-4 years reversal per 4 weeks input — a spike of longevity escape velocity.